African-American factor VII-deficient variants in Georgia (FVII variants).
We studied African-American Factor (FVII)-deficient variants and carriers in Georgia by measuring their levels of FVII antigen (FVIIAG) and FVII procoagulant (FVIIC). Factor VIIAG was determined using enzyme-linked immunoassay (ELISA), whereas FVIIC was measured in two ways: 1) by fibrin clotting methods that employed human recombinant (HRFVIIC), human placental (HPFVIIC), rabbit brain (RBFVIIC), and bovine brain (BBFVIIC) thromboplastins; and 2) by an amidolytic method (AMFVIIC). Prothrombin time tests (PT) were also performed by standard methods. These 4 FVII-deficient patients and 3 carriers demonstrated the following results: PT: 18.2 +/- 6.5 sec; FVIIAG: 73.0 +/- 14.9%; HRFVIIC: 30.6 +/- 20.3%; HPFVIIC: 30.5 +/- 21.4%; RBFVIIC: 25.3 +/- 21.4%; BBFVIIC: 30.6 +/- 17.5%; AMFVIIC: 44.1 +/- 18.3%. We conclude that a group of clinically mild African-American FVII-deficient variants exists in Georgia. This group is characterized by the presence of FVIIAG and decreased FVIIC, using a variety of thromboplastins; and excellent correlation was noted for both human thromboplastins.
Krauss
J S
JS
Department of Pathology, Medical College of Georgia, Augusta 30912-3620.
Matthews
A
A
Oliver
J
J
Lightsey
A
A
Jonah
M H
MH
Pantazis
C G
CG
D000906:Antibodies / Q000032:analysis / Q000276:immunology; D044383:Black People / Q000235:genetics*; D001923:Brain Chemistry; D004797:Enzyme-Linked Immunosorbent Assay; D005167:Factor VII / Q000032:analysis / Q000235:genetics* / Q000276:immunology; D005168:Factor VII Deficiency / Q000453:epidemiology / Q000235:genetics*; D014644:Genetic Variation; D005845:Georgia / Q000453:epidemiology; D006801:Humans; D010314:Partial Thromboplastin Time; D013925:Thromboplastin / Q000032:analysis / Q000235:genetics; D014481:United States; D001741:Black or African American
D000906:Antibodies; D005167:Factor VII; D013925:Thromboplastin